Rohto Pharmaceutical Co (FRA:UC1) Cyclically Adjusted Revenue per Share: €5.68 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UC1 Rohto Pharmaceutical Co Ltd FRA:UC1
69 GF Score
Price €12.50
GF Value €18.88
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Rohto Pharmaceutical Co FRA:UC1 -0.79% 69 Cyclically Adjusted Revenue per Share is €5.68 as of Mar. 2026. GuruFocus rates FRA:UC1 with a GF Score™ of 69/100 and a GF Value™ of €18.88 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Rohto Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was €2.096. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €5.68 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Rohto Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 8.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Rohto Pharmaceutical Co was 9.50% per year. The lowest was 4.70% per year. And the median was 7.15% per year.

As of today (2026-08-06), Rohto Pharmaceutical Co's current stock price is €12.50. Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €5.68. Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 2.20.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Rohto Pharmaceutical Co was 4.86. The lowest was 1.94. And the median was 2.49.


Rohto Pharmaceutical Co  (FRA:UC1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=12.50/5.68
=2.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Rohto Pharmaceutical Co was 4.86. The lowest was 1.94. And the median was 2.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Rohto Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 5.68

Rohto Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 5.85 5.80 5.62 5.68

FRA:UC1 vs PG, CL, KVUE: Cyclically Adjusted Revenue per Share Comparison

For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rohto Pharmaceutical Co Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


FRA:UC1
69GF Score
Rohto Pharmaceutical Co Ltd FRA:UC1
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rohto Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.096/112.7000*112.7000
=2.096

Current CPI (Mar. 2026) = 112.7000.

Rohto Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.219 98.100 1.400
201609 1.469 98.000 1.689
201612 1.431 98.400 1.639
201703 1.565 98.100 1.798
201706 1.259 98.500 1.441
201709 1.408 98.800 1.606
201712 1.490 99.400 1.689
201803 1.597 99.200 1.814
201806 1.381 99.200 1.569
201809 1.556 99.900 1.755
201812 1.625 99.700 1.837
201903 1.705 99.700 1.927
201906 1.498 99.800 1.692
201909 1.791 100.100 2.016
201912 1.718 100.500 1.927
202003 1.850 100.300 2.079
202006 1.399 99.900 1.578
202009 1.557 99.900 1.756
202012 1.613 99.300 1.831
202103 1.735 99.900 1.957
202106 1.394 99.500 1.579
202109 1.642 100.100 1.849
202112 1.801 100.100 2.028
202203 1.862 101.100 2.076
202206 1.613 101.800 1.786
202209 1.789 103.100 1.956
202212 2.017 104.100 2.184
202303 1.906 104.400 2.058
202306 1.746 105.200 1.870
202309 1.848 106.200 1.961
202312 2.040 106.800 2.153
202403 1.870 107.200 1.966
202406 1.759 108.200 1.832
202409 1.948 108.900 2.016
202412 2.356 110.700 2.399
202503 2.243 111.100 2.275
202506 2.177 111.700 2.196
202509 2.050 112.000 2.063
202512 2.084 113.000 2.078
202603 2.096 112.700 2.096

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €5.68 mean?
Rohto Pharmaceutical Co (FRA:UC1) has a Cyclically Adjusted Revenue per Share of €5.68 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Rohto Pharmaceutical Co and its competitors.
Is Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Rohto Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is €5.68. Overall, Rohto Pharmaceutical Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to PG and CL?
Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share of €5.68 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted Revenue per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Rohto Pharmaceutical Co and its competitors. Rohto Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is €5.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co (FRA:UC1) is currently considered Significantly Undervalued. The stock's GF Value™ is €18.88, compared to a current price of €12.50 — trading 33.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €5.68. Rohto Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Rohto Pharmaceutical Co (FRA:UC1), the current Cyclically Adjusted Revenue per Share is €5.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rohto Pharmaceutical Co (FRA:UC1) Overvalued in 2026?

Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued. The current stock price of €12.50 is trading 33.8% below its estimated GF Value™ of €18.88. GuruFocus considers Rohto Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for FRA:UC1:

  • Cyclically Adjusted Revenue per Share: €5.68
  • GF Value™: €18.88 vs. price of €12.50 (33.8% below fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the FRA:UC1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rohto Pharmaceutical Co Business Description

Other Exchanges RPHCF:USA4527:Japan
Address 1-8-1 Tatsuminishi, Ikuno-ku, Osaka, JPN, 544-8666
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
69GF Score

Get the complete analysis for FRA:UC1

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.50
Price
€18.88
GF Value